Media Centre

 

MSD abides by Medicines Australia’s Code of Conduct and the Therapeutic Goods Act.​

​Both prohibit a pharmaceutical company from direct to consumer advertising which includes issuing public press statements about our prescription medicines. We are able to issue public statements to advise registration of a new medicine, a reimbursement notice of a new medicine or any general corporate news not related to our medicines. For any specific issues please contact the Communications Manager.

Latest news:


28/10/18: Government subsidy for KEYTRUDA ® (pembrolizumab) to help fight Australia’s leading cause of cancer death 1,2

MSD is committed to providing access to KEYTRUDA for eligible lung cancer patients. Today marks a crucial first step in providing reimbursed immunotherapy as a first-line treatment for thousands of eligible Australians battling a type of advanced. More

17/08/18: Government today poised to consider innovative access solutions for cancer treatments

MSD Australia welcomes the Pharmaceutical Benefits Advisory Committee’s (PBAC) consideration of proposals to subsidise immuno-oncology (IO) medicines across multiple tumour types for Australian cancer patients at a Special Meeting being held today. More

29/06/18: Government urged to fund potentially lifesaving immunotherapy cancer medicines

MSD Australia today acknowledged the work being undertaken by Federal Health Minister, The Hon Greg Hunt MP to drive increased access to immuno-oncology (IO) medicines through a multi-cancer approach and urged the government to commit appropriate funds. More

21/02/18: Third year running - MSD recognised as Employer of Choice for Gender Equality

Australia’s Workplace Gender Equality Agency (WGEA) has today recognised MSD, a leading biopharmaceutical company, as an Employer of Choice for Gender Equality (EOCGE). More

29/08/17: Lung cancer patients die sooner in Australia than Taiwan – new analysis

Australians with advanced lung cancer are unlikely to survive longer than two years after they commence treatment, according to new research which has highlighted the limitations of chemotherapy as a front-line defence against the nation’s leading cancer killer more

10/05/2017: Federal Budget: MSD welcomes investment fund for new medicines

MSD today welcomed the Treasurer’s announcement that a new fund will be created to invest in innovative new medicines more

30/01/2017: Report shows more work is needed in fight against cardiovascular disease

MSD today welcomed many of the recommendations proposed in a report made public by the Department of Health as part of a Post-market Review into MSD’s cholesterol lowering medicine Ezetimibe (the product). more

25/01/2017: ‘Head in the sand’ attitude may put hearts at risk – new research

New research reveals that ageing Australians consider themselves thinner, fitter and healthier than they actually are, placing many in the firing line for life-threatening heart attack and stroke. more

18/01/2017: MSD welcomes new Minister for Health

MSD today welcomed the Prime Minister’s announcement that the Hon. Greg Hunt will be taking over as the Minister for Health, and Minister for Sport. more

05/11/2015: MSD awarded Employer of Choice for Gender Equality

The Workplace Gender Equality Agency (WGEA) has today awarded MSD the Employer of Choice for Gender Equality citation for 2015. more

24/06/2015: MSD and One Disease Announce $1.2 Million to Improve Indigenous Life Expectancy

The goal of closing the life-expectancy gap between Indigenous and non-Indigenous Australians is now one-step closer thanks to a $1.2 million donation to the cause today. MSD in Australia, a subsidiary of Merck & Co. Inc. donated $600,000 to not-for-profit organisation One Disease, which is also being matched dollar-for-dollar by an unnamed benefactor... more

MEDIA

Peter Bayliss

Communications Manager

Phone: +61 417 446 325

Peter.bayliss@merck.com